BC
KROS icon

BIT Capital’s Keros Therapeutics KROS Stock Holding History

BIT Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,237
Closed -$1.52M – 125
2024
Q3 		$1.52M Buy
26,237
+3,499
+15% +$173K 0.14% 57
2024
Q2 		$1.04M Buy
22,738
+10,795
+90% +$580K 0.08% 78
2024
Q1 		$791K Buy
11,943
+1,512
+14% +$89.7K 0.06% 96
2023
Q4 		$415K Buy
10,431
+3,469
+50% +$109K 0.04% 63
2023
Q3 		$222K Hold
6,962
– – 0.03% 82
2023
Q2 		$280K Buy
+6,962
New +$305K 0.03% 101
2023
Q1 		– Sell
-1,330
Closed -$63.9K – 163
2022
Q4 		$63.9K Buy
+1,330
New +$62.1K 0.01% 126
2022
Q2 		– Sell
-1,700
Closed -$92.4K – 146
2022
Q1 		$92.4K Buy
+1,700
New +$87.3K 0.01% 107

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BIT Capital's KROS Position: Q4 2024 in Review

BIT Capital sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 26,237 shares — an estimated $1.52M sold.

BIT Capital first reported a position in KROS in Q1 2022 and held it in 8 quarters. The position peaked at $1.52M in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • BIT Capital reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • BIT Capital sold 26,237 Keros Therapeutics shares in Q4 2024, an estimated $1.52M.
  • BIT Capital first reported a position in Keros Therapeutics in Q1 2022 and held it in 8 quarters.
  • BIT Capital's Keros Therapeutics position peaked at $1.52M in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on BIT Capital's 13F filing for Q4 2024, filed 12 Feb 2025.